UroGen Pharma (NasdaqGM:URGN) reported new Phase 3 ENVISION trial analyses for ZUSDURI in recurrent low grade intermediate ...
To gain new insights into the use of urinary tumor DNA (utDNA), a promising biomarker in the diagnosis, monitoring, and prognosis of bladder cancer, an international team of researchers conducted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results